Thymosin Alpha-1
Tα1 / Thymalfasin / Zadaxin
28-amino acid immune-modulating peptide derived from the thymus gland. Approved in 70+ countries as Zadaxin. Among the most clinically validated peptides globally.
Mechanism of action
Activates dendritic cells and T-helper cells, enhances NK cell activity, upregulates MHC class I and II expression, stimulates IL-2 and interferon production. Regulates rather than simply stimulates immune response — useful for both underactive and dysregulated immunity.
Effects in the body
Thymosin Alpha-1 calibrates immune response. This bidirectional modulation makes it useful for both underactive immunity (infections, cancer support) and overactive immune states. Among the most clinically validated peptides globally — just not specifically in the USA.
Pros & cons (from the literature)
- Approved and used clinically in 70+ countries as Zadaxin
- Strong published evidence for hepatitis B and C, sepsis, and cancer immunotherapy support
- Vaccine response enhancement data from clinical trials
- 30+ years of international safety data
- Non-immunosuppressive autoimmune modulation
- Zadaxin not specifically FDA-approved in the USA
- Expensive per dose compared to other peptides
- Some caution needed in certain autoimmune conditions
- Injection required — no oral form
- Quality control varies significantly by source
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
Multiple published randomized controlled trials globally for hepatitis, sepsis, and influenza. Phase II and III cancer immunotherapy data exists. Strong safety profile established over 30+ years of international clinical use.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.